42 in Pediatric Nephrology
50 in Pediatric Neurology and Neurosurgery
“To continue to be ranked among the nation’s best children’s hospitals, particularly following a year in which the nation and the world faced a monumental health crisis, is a testament to the dedication of our exceptional team,” says Pamela Johnson-Carlson, chief administrative officer of UI Stead Family Children’s Hospital. “This is a true honor and really points to our commitment to providing the top-quality care our patients and families have come to expect from this team.”
“Our extraordinary team of physicians, nurses, researchers, and staff continue their years-long commitment to providing the best care and treatment not only for Iowa’s children, but for children from across the country and around the world – a feat that was even more commendable this past year during a global pandemic,” says Eva Tsalikian, MD, interim physician-in-chief at UI Stead Family Children’s Hospital and in
University of Iowa Children s Hospital at No 15 in first U S News Midwest rankings
thegazette.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thegazette.com Daily Mail and Mail on Sunday newspapers.
UI Stead Family Children s Hospital ranks in five specialties
uiowa.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from uiowa.edu Daily Mail and Mail on Sunday newspapers.
Science for just $15 USD.
Prolonged prevention of autoimmune diabetes
Teplizumab was previously shown in a clinical trial to delay onset of type 1 diabetes (T1D) in high-risk relatives of individuals with T1D. Now, Sims
et al. extend the follow-up analysis of this trial by 12 months, finding that efficacy of the initial 2-week treatment course persisted, with an extended time to T1D diagnosis in the teplizumab-treated group. Clinical benefits associated with reversed C-peptide decline improved beta cell function and partial exhaustion in CD8
+ T cells in the treated patients. HbA1c did not differ between placebo and treatment groups. This follow-up study further supports the use of anti-CD3 treatment for the prevention of T1D.